Industry News

Patent Announced Covering Use of Filamentous Phage as Gene Therapy Vectors

Published in Gene Therapy Weekly, July 6th, 2000

Selective Genetics, Inc., San Diego, California, announced that the U.S. Patent Office issued Patent No. 6,054,312 entitled "Receptor-mediated gene delivery using bacteriophage vectors" to the company.

This broad patent covers compositions of filamentous phage and phagemid particles that present a ligand, or binding protein, to its mammalian cell receptor to deliver therapeutic genes.

The company believes the importance of this invention for gene therapy is underscored by an industry-wide desire for safer and more efficient gene delivery vehicles. Phage offer an alternative to existing vectors and strike a balance between the advantages and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry